Universal Ibogaine Past Earnings Performance
Past criteria checks 0/6
Universal Ibogaine has been growing earnings at an average annual rate of 10.4%, while the Healthcare industry saw earnings growing at 16.2% annually. Revenues have been growing at an average rate of 61.2% per year.
Key information
10.4%
Earnings growth rate
59.8%
EPS growth rate
| Healthcare Industry Growth | -6.7% |
| Revenue growth rate | 61.2% |
| Return on equity | -100.2% |
| Net Margin | -66.9% |
| Last Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Universal Ibogaine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 24 | 2 | -2 | 1 | 0 |
| 31 Jan 24 | 2 | -1 | 1 | 0 |
| 31 Oct 23 | 2 | -2 | 1 | 0 |
| 31 Jul 23 | 1 | -2 | 2 | 0 |
| 30 Apr 23 | 1 | -6 | 2 | 0 |
| 31 Jan 23 | 1 | -7 | 3 | 0 |
| 31 Oct 22 | 1 | -7 | 4 | 0 |
| 31 Jul 22 | 1 | -10 | 5 | 0 |
| 30 Apr 22 | 1 | -8 | 5 | 0 |
| 31 Jan 22 | 1 | -8 | 5 | 0 |
| 31 Oct 21 | 0 | -7 | 5 | 0 |
| 31 Jul 21 | 0 | -4 | 4 | 0 |
| 30 Apr 21 | 0 | -6 | 4 | 0 |
| 31 Jul 20 | 0 | -6 | 2 | 0 |
Quality Earnings: IBO is currently unprofitable.
Growing Profit Margin: IBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IBO is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare IBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBO is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (10.4%).
Return on Equity
High ROE: IBO has a negative Return on Equity (-100.24%), as it is currently unprofitable.